Tag: CVRX
CVRx initiates BENEFIT-HF trial of Barostim device in “significantly expanded population”
CVRx recently announced the start of the BENEFIT-HF clinical trial, a randomised study designed to evaluate the impact of the Barostim neuromodulation device in...
CVRx launches new version of neuromodulation device intended to treat heart...
CVRx—the developer of the “world’s first” US Food and Drug Administration (FDA)-approved neuromodulation device to treat the symptoms of heart failure—has launched its new...
New vice president of US market development for CVRx
CVRx has appointed Tom Moore to the newly created, officer position of vice president, US Market Development. In this role, Moore will lead all field efforts...